Up­dat­ed: No­var­tis re­jigs late-stage plans for Cosen­tyx, next-gen CAR-T, TIG­IT an­ti­body and more

No­var­tis has cleaned up its Phase III slate, shelv­ing late-stage plans for pro­grams across in­flam­ma­to­ry dis­eases and can­cer, the Swiss phar­ma gi­ant dis­closed in its quar­ter­ly up­date — while al­so putting a mid-stage Hunt­ing­ton’s drug to bed and switch­ing things up for a key rare dis­ease can­di­date.

The biggest change came in the de­ci­sion to aban­don a Phase III tri­al for Cosen­tyx, No­var­tis’ block­buster IL-17A an­ti­body, in ac­tive pe­riph­er­al spondy­loarthri­tis. It didn’t end up re­cruit­ing any of the 324 pa­tients planned be­fore ter­mi­nat­ing the tri­al ear­li­er this month due to a “strate­gic de­ci­sion of se­nior man­age­ment,” ac­cord­ing to records on clin­i­cal­tri­als.gov.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.